Atara Biotherapeutics To Present New Tab-cel® Clinical Data During Oral Session At ESMO Immuno-Oncology Annual Congress 2023
Portfolio Pulse from Benzinga Newsdesk
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) announced positive new data for tabelecleucel (tab-cel®) in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease involving the CNS. The data, which will be presented at the ESMO Immuno-Oncology Congress, shows a 77.8% Objective Response Rate in 18 patients. This pooled analysis includes data from the Phase 2 EBVision Trial and is consistent with previous experiences.
November 30, 2023 | 6:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atara Biotherapeutics announced positive clinical data for tab-cel® with a high Objective Response Rate, which will be presented at an upcoming ESMO Congress, potentially boosting investor confidence.
The announcement of positive clinical data typically has a favorable impact on a biotech company's stock price in the short term, as it reflects progress in product development and potential for future revenue growth. The presentation at a prestigious congress like ESMO further validates the significance of the data.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100